Axion Biosystems specializes in neural interfacing technologies with wide applicability to the research, clinical and drug discovery markets.  Axion has developed the next generation, multi-electrode array (MEA) technology to provide unprecedented access to cellular information at a reasonable cost.  The companiy offers 64- and 768-channel MEA systems that incorporate priorietary technology for simultaneous stimulation and recording of neural tissue.  Current development is focused on pharmaceutical drug screening.  Axion's platform technology was developed by Drs. Stephen DeWeerth and Mark Allen at Georgia Institute of Technology.
www.axionbiosystems.com